These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 15104192)
21. Specific immunotherapy in honeybee venom allergy: a comparative study using aqueous and aluminium hydroxide adsorbed preparations. Ruëff F; Wolf H; Schnitker J; Ring J; Przybilla B Allergy; 2004 Jun; 59(6):589-95. PubMed ID: 15147443 [TBL] [Abstract][Full Text] [Related]
22. Comparative study of cluster and conventional immunotherapy schedules with dermatophagoides pteronyssinus in the treatment of persistent allergic rhinitis. Zhang L; Wang C; Han D; Wang X; Zhao Y; Liu J Int Arch Allergy Immunol; 2009; 148(2):161-9. PubMed ID: 18802361 [TBL] [Abstract][Full Text] [Related]
23. Sublingual-oral administration of standardized allergenic extracts: phase 1 safety and dosing results. Esch RE; Bush RK; Peden D; Lockey RF Ann Allergy Asthma Immunol; 2008 May; 100(5):475-81. PubMed ID: 18517081 [TBL] [Abstract][Full Text] [Related]
24. Safety of immunotherapy in patients with rhinitis, asthma or atopic dermatitis using an ultra-rush buildup. A retrospective study. Cardona R; Lopez E; Beltrán J; Sánchez J Allergol Immunopathol (Madr); 2014; 42(2):90-5. PubMed ID: 23265265 [TBL] [Abstract][Full Text] [Related]
25. Skin test reactivity to indoor allergens as a marker of asthma severity in children with asthma. Sarpong SB; Karrison T Ann Allergy Asthma Immunol; 1998 Apr; 80(4):303-8. PubMed ID: 9564978 [TBL] [Abstract][Full Text] [Related]
26. Nasal immunotherapy in weed-induced allergic rhinitis. Gaglani B; Borish L; Bartelson BL; Buchmeier A; Keller L; Nelson HS Ann Allergy Asthma Immunol; 1997 Sep; 79(3):259-65. PubMed ID: 9305235 [TBL] [Abstract][Full Text] [Related]
27. Incidence of systemic reactions during rush immunotherapy. Portnoy J; King K; Kanarek H; Horner S Ann Allergy; 1992 Jun; 68(6):493-8. PubMed ID: 1610025 [TBL] [Abstract][Full Text] [Related]
28. Safety, tolerability and clinical efficacy of ultra-rush sublingual immunotherapy among patients suffering from allergic rhinitis. Balaji R; Parasuramalu BG; Chandregowda BV; Gangaboraiah Allergol Immunopathol (Madr); 2014; 42(3):216-23. PubMed ID: 23481554 [TBL] [Abstract][Full Text] [Related]
29. Double-blind, placebo-controlled study with a modified therapeutic vaccine of Salsola kali (Russian thistle) administered through use of a cluster schedule. Colás C; Monzón S; Venturini M; Lezaun A J Allergy Clin Immunol; 2006 Apr; 117(4):810-6. PubMed ID: 16630938 [TBL] [Abstract][Full Text] [Related]
30. [Specific skin reactions induced by individual pollen preparations in hypersensitivity persons]. Paranos S; Petrović S; Vojović I Srp Arh Celok Lek; 1998; 126(9-10):362-7. PubMed ID: 9863408 [TBL] [Abstract][Full Text] [Related]
31. Safety of rush immunotherapy using a modified schedule: a cumulative experience of 893 patients receiving multiple aeroallergens. Smits WL; Giese JK; Letz KL; Inglefield JT; Schlie AR Allergy Asthma Proc; 2007; 28(3):305-12. PubMed ID: 17619559 [TBL] [Abstract][Full Text] [Related]
32. House dust mite and cockroach exposure are strong risk factors for positive allergy skin test responses in the Childhood Asthma Management Program. Huss K; Adkinson NF; Eggleston PA; Dawson C; Van Natta ML; Hamilton RG J Allergy Clin Immunol; 2001 Jan; 107(1):48-54. PubMed ID: 11149990 [TBL] [Abstract][Full Text] [Related]
33. Side-effects of injective allergen immunotherapy administered to intermittent or persistent allergic rhinitis patients. Rogala B; Markiewicz-Bendkowska IB; Brzoza Z; Glück J; Oleś E Rhinology; 2007 Jun; 45(2):134-9. PubMed ID: 17708460 [TBL] [Abstract][Full Text] [Related]
34. Allergic rhinitis due to house dust mites: evaluation of the efficacy of specific sublingual immunotherapy. Tonnel AB; Scherpereel A; Douay B; Mellin B; Leprince D; Goldstein N; Delecluse P; Andre C Allergy; 2004 May; 59(5):491-7. PubMed ID: 15080829 [TBL] [Abstract][Full Text] [Related]
35. Evaluation of serum s-IgE/total IgE ratio in predicting clinical response to allergen-specific immunotherapy. Di Lorenzo G; Mansueto P; Pacor ML; Rizzo M; Castello F; Martinelli N; Ditta V; Lo Bianco C; Leto-Barone MS; D'Alcamo A; Di Fede G; Rini GB; Ditto AM J Allergy Clin Immunol; 2009 May; 123(5):1103-10, 1110.e1-4. PubMed ID: 19356792 [TBL] [Abstract][Full Text] [Related]
36. Skin prick reaction and nasal provocation response in diagnosis of nasal allergy to the house dust mite. Kanthawatana S; Maturim W; Fooanan S; Trakultivakorn M Ann Allergy Asthma Immunol; 1997 Nov; 79(5):427-30. PubMed ID: 9396976 [TBL] [Abstract][Full Text] [Related]
37. Clinical experience with specific immunotherapy to horse dander. Fernández-Távora L; Rico P; Martín S J Investig Allergol Clin Immunol; 2002; 12(1):29-33. PubMed ID: 12109529 [TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of specific immunotherapy to mosquito bites. Ariano R; Panzani RC Eur Ann Allergy Clin Immunol; 2004 Apr; 36(4):131-8. PubMed ID: 15180354 [TBL] [Abstract][Full Text] [Related]
39. Utilization and cost of immunotherapy for allergic asthma and rhinitis. Donahue JG; Greineder DK; Connor-Lacke L; Canning CF; Platt R Ann Allergy Asthma Immunol; 1999 Apr; 82(4):339-47. PubMed ID: 10227332 [TBL] [Abstract][Full Text] [Related]
40. Safety of allergen immunotherapy: a review of premedication and dose adjustment. Morris AE; Marshall GD Immunotherapy; 2012 Mar; 4(3):315-22. PubMed ID: 22401636 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]